Vectura Plc: Evaluating the Effect of Product Success / Failure on Share Price

Torux Biotech together with Biostrategy Analytics have published an Analyst Report relating to Vectura Plc, a listed (LON:VEC) pharmaceutical company focused on Chronic Obstructive Pulmonary Disease (COPD) and Asthma indications. The report can be found in the link below:

Vectura Report

The aim of this report is to evaluate the effect of potential success / failure of clinical trial products on the share price of Vectura Plc using variations of risk Adjusted Net Present Value (rNPV) methodologies. In addition, a brief revenue & market analysis of the market segment in which Vectura is active, has been performed.